The efficacy of venetoclax in the treatment of myelodysplastic syndrome

Myelodysplastic syndrome (MDS) is a rare blood cancer that gradually affects the bone marrow's ability to produce normal blood cells and can cause symptoms such as weakness, frequent infections, anemia and fatigue. In some cases, MDS may progress to acute myeloid leukemia (AML). Venetoclax (Venetoclax), as the first new oral targeted drug that specifically targets the BCL-2 protein, has shown significant efficacy in the treatment of MDS.

2021YearJulyMonth21The U.S. Food and Drug Administration (FDA) was granted Breakthrough Therapy Designation (BTD) to venetoclax in combination with azacitidine for the treatment of previously untreated adult patients with intermediate, high, and very high-risk MDS. This designation is based on a phase Ib, open-label, non-randomized, multicenter dose-finding study (the M15-531 study), which showed positive interim results.

According to clinical research data, venetoclax combined with azacitidine has shown significant efficacy in the treatment of MDS. This treatment option can selectively target and inhibit BCL-2 and inhibit its activity, thereby restoring the process of tumor cell apoptosis. This ability to restore tumor cell apoptosis helps reduce the number of abnormal cells, thereby improving patients' symptoms and quality of life.

In addition to its remarkable efficacy, venetoclax also shows good safety and tolerability in the treatment of MDS. Although patients may experience some side effects, such as nausea, diarrhea, and fatigue, most of these side effects are controllable and will gradually lessen as treatment progresses.

Venetoclax as the first drug targeting BCL-2's targeted drugs have made breakthrough progress in the treatment ofMDS. It not only provides new treatment options for patients, but also provides new directions for future research. With the deepening of research and the accumulation of clinical data, we have reason to believe that the efficacy of venetoclax in the treatment of MDS will be more accurate and significant.